TH-1 Dendritic Cell Immunotherapy

Phase 1Biologic

TH-1 Dendritic Cell Immunotherapy is one of 18 biologic programs targeting Adult Glioblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult GlioblastomaActive, not recruiting

Adult GlioblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Adult Glioblastoma

#DrugCompanyPhaseTrials

Eloxatin

Erivedge

Iressa

Trisenox

Torisel

PPrism Pharmaceuticals

Cyramza

TKI258

Zarnestra

Olaratumab

Fenretinide

EEastern Cooperative Oncology Group

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult Glioblastoma1 trial

Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma

Completed·TThe Cooper Health System·Phase 1·NCT04552886·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TH-1 Dendritic Cell Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TH-1 Dendritic Cell Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TH-1 Dendritic Cell Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cooper Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Cooper Health System

TH-1 Dendritic Cell Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News